Novo A/S
| Private limited company | |
| Industry | Life science |
| Headquarters | Gentofte, Denmark |
Key people | Eivind Kolding(CEO), Sten Scheibye(Chairman) |
| Website | www.novo.dk |
Novo A/S is a holding company in the Novo Group. It is a private limited liability fully owned by the Novo Nordisk Foundation. It is a majority shareholder in Novo Nordisk A/S and Novozymes A/S.and manage the Novo Nordisk Foundation's financial assets. Eivind Kolding succeeded Henrik Gürtler as CRO on 1 May 2014.[1]
Investments
- In May 2013, Novo acquired all shares in the pharmatheutical company Xellia.[2]
- Im July 2914, Novo A/S acquired all shares in Sonion, a manufacturer of components for the hearing aid industry.[3]
References
- ↑ "Eivind Kolding bliver direktør for Novo A/S" (in Danish). Berlingske. Retrieved 2014-07-17.
- ↑ "Novo køber norsk biotekselskab for fire milliarder kroner" (in Danish). Ingeniøren. Retrieved 2014-07-17.
- ↑ "Novo betaler op mod 4 milliarder kroner for Sonion" (in Danish). Berlingske. Retrieved 2014-07-17.